New drug IBI363 targets Hard-to-Treat cancers in early trial
NCT ID NCT05290597
First seen Mar 05, 2026 · Last updated Jun 16, 2026 · Updated 16 times
Summary
This early-phase study tests a new drug called IBI363 in about 40 people with advanced solid tumors or lymphomas that haven't responded to other treatments. The main goal is to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body and look for any signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES OR LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care Wollongong
Sydney, New South Wales, 2500, Australia
-
Sydney, New South Wales, 2109, Australia
-
Sydney Southwest Private Hospital
Sydney, New South Wales, 2170, Australia
-
Westmead Hospital
Sydney, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.